

PATENT

2. (Reiterated) The therapeutic agent according to claim 1, used for administration to the ischemic site.
3. (Amended) The therapeutic agent according to claim 1, wherein the diabetic ischemic disease is selected from the group consisting of diabetic lower limb ischemic disease, diabetic ischemic neuropathy and diabetic ischemic myocardial infarction.
4. (Reiterated) The therapeutic agent according to claim 3, wherein the diabetic ischemic disease is diabetic lower limb ischemic disease.
5. (Amended) The therapeutic agent according to claim 1 wherein the administration is into the muscle of the ischemic site.
6. (Amended) The therapeutic agent according to claim 1, wherein the nucleic acid encoding the HGF is in the form of a Sendai virus (HVJ)-liposome.
7. (Amended) The therapeutic agent according to claim 1 wherein the administration is repeated.
8. (Amended) The therapeutic agent according to claim 1 comprising at least 50  $\mu$ g of the nucleic acid encoding the HGF.
9. (Amended) A method for the treatment of a diabetic ischemic disease, comprising administering a therapeutically effective amount of a nucleic acid encoding hepatocyte growth factor, thereby treating the diabetic ischemic disease.
10. (Reiterated) The method according to claim 9, wherein the HGF gene is administered to an ischemic site.

PATENT

11. (Amended) The method according to claim 9, wherein the diabetic ischemic disease is selected from the group consisting of diabetic lower limb ischemic disease, diabetic ischemic neuropathy and diabetic ischemic myocardial infarction.

12. (Reiterated) The method according to claim 11, wherein the diabetic ischemic disease is diabetic lower limb ischemic disease.

13. (Amended) The method according to claim 9, wherein the nucleic acid encoding HGF is administered into the muscle of ischemic site.

14. (Amended) The method according to claim 9, wherein the HGF gene is in the form of a Sendai virus (HVJ)-liposome.

15. (Amended) The method according to claim 9, wherein the nucleic acid encoding the HGF is administered repeatedly.

16. (Amended) The method according to claim 9, wherein at least 50  $\mu$ g of the nucleic acid encoding the HGF is administered to the subject.

17. (Amended) Use of a nucleic acid encoding HGF for preparing therapeutic agents for diabetic ischemic disease.

18. (Amended) The use according to claim 17, wherein the diabetic ischemic disease is selected from the group consisting of diabetic lower limb ischemic disease, diabetic ischemic neuropathy and diabetic ischemic myocardial infarction.

19. (Reiterated) The use according to claim 18, wherein the diabetic ischemic disease is diabetic lower limb ischemic disease.